Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $17.48, but opened at $18.13. Telix Pharmaceuticals Limited American Depositary Shares shares last traded at $17.56, with a volume of 2,682 shares traded.
Wall Street Analyst Weigh In
TLX has been the topic of several recent analyst reports. William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a research note on Wednesday, March 12th. Wedbush began coverage on Telix Pharmaceuticals Limited American Depositary Shares in a report on Thursday. They set an "outperform" rating and a $22.00 price target for the company.
Read Our Latest Report on TLX
Telix Pharmaceuticals Limited American Depositary Shares Trading Down 3.4%
The stock's fifty day moving average price is $16.76 and its two-hundred day moving average price is $16.85.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Telix Pharmaceuticals Limited American Depositary Shares stock. Private Advisor Group LLC bought a new position in shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 10,140 shares of the company's stock, valued at approximately $170,000.
About Telix Pharmaceuticals Limited American Depositary Shares
(
Get Free Report)
Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.
Read More
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
